symptoms prior to the onset of action of DMARDs, treatment should be limited to the lowest effective dose for the shortest duration possible Conventional synthetic DMARDs Conventional synthetic DMARDs are strongly recommended for inadequate response to or intolerance of NSAIDs and/or IAGCs for active TMJ arthritis. Methotrexate is conditionally recommended as a preferred agent over leflunomide. The TMJ is a high-risk joint due to major impact on activities of daily living, and thus, early use